LONDON (Alliance News) - Shield Therapeutics PLC said on Wednesday said the Swiss Agency for Therapeutic Products has approved the Feraccru product to treat iron deficiency in adults with or without anaemia.
The approval is expected to increase the commercial opportunity for Feraccru, which has first approved in the EU and Switzerland for the treatment of iron deficiency anaemia, for adult patients with inflammatory bowel disease.
"We are delighted with the positive progress we continue to make with regulatory authorities in relation to maximising the commercial opportunity for Feraccru. Switzerland represents an attractive market opportunity as it is both well reimbursed and has a much higher level of treatment penetration compared to other markets, particularly for IV iron therapies," said Chief Executive Officer Carl Sterritt.
Shares in the iron deficiency-focused pharmaceutical company were up 2.1% at 85.25 pence on Wednesday
Shield Thera (STX)